Inventor · Stanford, CA, US

Stephen Willingham

18Patents
5h-index
16Co-inventors
55Inventor score

Filing activity: Feb 26, 2014 → Feb 3, 2023

Most-cited inventions

PatentTitleAreaCited byStatus
US9623079B2 Methods for achieving therapeutically effective doses of anti-CD47 agents for treating cancer Emerging Cross-Sectional Technologies 13 Active
US10301387B2 Methods for achieving therapeutically effective doses of anti-CD47 agents Emerging Cross-Sectional Technologies 11 Active
US10064925B2 Use of anti-CD47 agents to enhance immunization Chemistry; Metallurgy 7 Active
US11136391B2 Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody Emerging Cross-Sectional Technologies 6 Active
US10344094B2 Treatment of cancer with dual targeting of CD47 and EGFR Chemistry; Metallurgy 6 Active
US11518806B2 Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody Emerging Cross-Sectional Technologies 4 Active
US11603404B2 Methods for treating cancer by achieving therapeutically effective doses of anti-CD47 antibody Emerging Cross-Sectional Technologies 2 Active
US10912776B2 Methods of treating cancer Chemistry; Metallurgy 1 Active
US11040040B2 Methods of treating cancer Chemistry; Metallurgy 1 Active
US11154600B2 Use of anti-CD47 agents to enhance immunization Chemistry; Metallurgy 0 Active
US12116635B2 Methods for detecting and treating cancers having adenosine pathway activation Physics 0 Active
US12258399B2 Methods for achieving therapeutically effective doses of anti-CD47 agents Emerging Cross-Sectional Technologies 0 Active
US12023337B2 Methods of treating cancer Chemistry; Metallurgy 0 Active
US12174192B2 Methods for detecting and treating cancers having adenosine pathway activation Physics 0 Active
US11104731B2 Compositions for achieving therapeutically effective doses of anti-CD47 agents Emerging Cross-Sectional Technologies 0 Active
US12037402B2 Treatment of cancer with dual targeting of CD47 and EGFR Chemistry; Metallurgy 0 Active
US12258403B2 Methods for treating myeloma by achieving therapeutically effective doses of anti-CD47 antibody Emerging Cross-Sectional Technologies 0 Active
US11130813B2 Treatment of cancer with dual targeting of CD47 and EGFR Chemistry; Metallurgy 0 Active

Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.